Vaxart Says COVID-19 Vaccine Selected for Operation Warp Speed

Vaxart has announced that its COVID-19 vaccine has been selected to participate in an animal study on primates funded by the Trump administration’s Operation Warp Speed.

The California-based drugmaker is developing an oral COVID-19 vaccine, which would be administered by tablet rather than injection.

The vaccine candidate is stable at room temperature, which offers “an enormous logistical advantage in large vaccination campaigns,” the company said.